We strategically use imaging, such as MRI, CT, and PET to accelerate drug development and lower investment risks. Whether you are entering a phase I/II and need early robust efficacy data or preparing a successful H2H or superiority trial, our science, operations and technology teams will work with you to develop the right solution.
IAG’s cloud platform for robust imaging data management in multi-centre trial setting and central review. One comprehensive software system to control trial progress, conduct central reads and use built-in AI for earlier read-outs and decision support.
Innovating together with promising life science companies and securing successful partnering arrangements has yielded spectacular results over the past 10 years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words.
Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.
From the Technology Innovation to the Entrepreneur of the Year, IAG’s team, its founder-CEO and its industry disrupting technology platform DYNAMIKA won 22 awards since 2007. We share, with pride and thanks!
ISO Quality Management System and SOPs audited by BSI and external partners. Regulatory clerance for DYNAMIKA platform.
![The image above is allustrating DCE MRI maps of a treatment responder pre-SABR (a-d) and post-SABR (e-h) including (left-right) IRE, AUC, Ktrans and Ve with tumour outlined in orange, generated with Dynamika [4]. The corresponding slice between pre-SABR and post-SABR scans.](https://www-test.ia-grp.com/wp-content/uploads/2017/09/RCC-400x377.jpg "RCC")
